• 1ST OCTOBER 2025

    Retrospective price adjustment for Bisoprolol 5mg/5ml oral solution for August 2025

    A licensed version of Bisoprolol 1mg/ml oral solution sugar free was launched by Aspire Pharma Ltd in August 2025. However, at the same time an unlicensed version of Bisoprolol 5mg/5ml oral solution was listed in Part VIIIB of the Drug Tariff. According to the Drug Tariff rules, any generically written prescription for Bisoprolol 5mg/5ml (or

    Read more
    • 1ST OCTOBER 2025

    Services and Regulatory changes coming into force today

    Today (Wednesday 1st October 2025), several service and regulatory changes have come into effect, as well as today being the start date for several national services. Below is a summary of all these service developments and regulatory changes. Commencement of services From today, pharmacies registered to provide the services, can start to provide the Childhood

    Read more
    • 30TH SEPTEMBER 2025

    Community Pharmacy England publishes 2024/25 Annual Report

    The 2024/25 annual report for Community Pharmacy England has been published, outlining what was another crucial year for the organisation and highlighting the breadth of work carried out on behalf of all community pharmacy owners. The year saw the first CPCF negotiations with the new Government, resulting in a positive step-change for the sector and

    Read more
    • 30TH SEPTEMBER 2025

    SLS endorsement requirements removed for Tadalafil and Vardenafil

    From 1 October 2025, generically written prescriptions for Tadalafil and Vardenafil preparations will no longer require the prescriber ‘SLS’ endorsement. However, the SLS endorsement requirements will continue to apply to the following branded versions – Cialis® and Levitra® which may only be ordered on NHS prescriptions issued for the treatment of erectile dysfunction in restricted circumstances.

    Read more
    • 30TH SEPTEMBER 2025

    Removal of prescribing restrictions on flu antivirals

    The NHS restrictions on prescribing of influenza antiviral treatments, Oseltamivir (Tamiflu®) and Zanamivir (Relenza®) have been relaxed to allow prescribing of these flu antivirals at any time of the year for patients in clinical at-risk groups as well as those who are at risk of severe illness and/or complications from flu if not treated. Previously, to

    Read more
    • 30TH SEPTEMBER 2025

    September 2025 Price Concessions Final Update

    The Department of Health and Social Care (DHSC) has today (30/09/2025) confirmed the following final list of price concessions for September 2025.  Drug Pack size Price concession Clotrimazole 1% cream 50 £3.67 Co-amoxiclav 250mg/62mg/5ml oral suspension sugar free 100 £4.52 Co-careldopa 12.5mg/50mg tablets 90 £5.01 Codeine 15mg/5ml linctus sugar free 200 £12.02 Paracetamol 500mg effervescent tablets 100

    Read more
    • 30TH SEPTEMBER 2025

    Update from our CEO: Influencing for the future

    “Advocacy work is continuing to ensure pharmacy’s value, potential and needs are factored into healthcare policy discussions at the highest levels,” writes Community Pharmacy England Chief Executive Janet Morrison in a new blog. In-depth analysis of critical funding issues, national media work, and implementation of service changes continued over the summer alongside Community Pharmacy England’s

    Read more
    • 30TH SEPTEMBER 2025

    October 2025 Category M prices announced

    The Drug Tariff Category M pricelist for October 2025 has been published on the NHS Business Services Authority (NHSBSA) website. At the end of Q4 2024/25 there remains an over delivery of medicine margin of circa £124m. Based on analysis of the Category M price list for October 2025, Community Pharmacy England estimates there will be

    Read more
    • 29TH SEPTEMBER 2025

    Community Pharmacy England expands research and LPC support capacity with new roles

    New positions have been created at Community Pharmacy England to increase our capacity for in-depth research and for LPC support, both of which are critical as we work to secure a sustainable future for community pharmacy. Experienced pharmacy leader and researcher Dr James Davies has been appointed as Director of Research and Insights at Community

    Read more
    • 29TH SEPTEMBER 2025

    Autumn Conference Season: Influencing for the future

    By Chief Executive Janet Morrison At Community Pharmacy England, work is continuing apace as we prepare for the next round of negotiations on the Community Pharmacy Contractual Framework (CPCF) and explore the implications of the NHS 10 Year Plan. Financial and economic analysis showing the depth of the ongoing funding crisis and the impact it

    Read more